Labiotech.eu

News and Trends 14 Jul 2022

Agomab bags $114 million in thriving regenerative medicine sector

The Belgian company Agomab Therapeutics has topped up its Series B round by $40.5 million to hit $114 million. This Pfizer-led financing round extension is just the latest sign that the emerging field of regenerative medicine is coming to the fore. Agomab has embarked on an ambitious path to redefine how we understand regenerative medicine […]

July 14, 2022 - 3 minutesmins - By Victor Kotsev

covid-19 vaccine emergency use authorization

News and Trends 14 Jul 2022

FDA authorizes the first protein-based COVID-19 vaccine in the US

Novavax, Inc. has been given emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for its adjuvanted, protein-based COVID-19 shot. Branded Nuvaxovid and Covovax outside the U.S., Novavax’s vaccine is already approved for use in several countries worldwide, including the EU, U.K., Canada, Australia, South Korea and India. During public health emergencies, […]

July 14, 2022 - 2 minutesmins - By Omnia Ibrahim

News and Trends 14 Jul 2022

Telo Genomics launches clinical study of drug resistance test for multiple myeloma

Canadian biotech company Telo Genomics Corp. has started the processing of clinical samples to evaluate its TeloView platform to identify multiple myeloma (MM) patients at high-risk of developing treatment resistance. The study is the second being carried out in collaboration with the Mayo Clinic to evaluate the company’s prognostic technology to address multiple unmet clinical […]

July 14, 2022 - 3 minutesmins - By Jim Cornall

In Depth 14 Jul 2022

Radiopharmaceuticals gain traction for cancer theranostics potential

After decades of neglect from big pharma, radiopharmaceuticals are generating major oncology deals globally. This could lead to a boom in cancer drugs that can serve as both treatments and diagnostics, or “theranostics.” Over the last few years, there has been big activity from companies developing drugs that use radioactivity to destroy tumors. Just this […]

July 14, 2022 - 5 minutesmins - By Jonathan Smith

More News! 13 Jul 2022

Paradigm of treatment of mental health to be transformed by gut-brain development program

Building on a decade of research, a development program for next-generation probiotics and therapeutics to modulate gut microbiota and mental health has been launched. Seed Health, a microbiome science company along with Axial Therapeutics, a clinical stage biopharmaceutical company announced the joint program in the US today (July 13). It will build on the work […]

July 13, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Jul 2022

First aseptic filling line and facilities completed in Taiwan

The construction of a fully-automated aseptic filling line and facilities has been finished in Taiwan. Amaran Biotechnology Inc., a subsidiary of Taiwan’s OBI Pharma Inc., made the announcement that the new facility, a first for the country, minimizes the risks of human factors affecting the quality of pharmaceutical products, and enhances their safety. The project […]

July 13, 2022 - 2 minutesmins - By Liza Laws

News and Trends 13 Jul 2022

Orthox green light for knee cartilage repair clinical trial

Orthox Limited, a clinical stage company developing medical implants to repair damaged knee articular cartilage and other orthopaedic injuries, can start its FFLEX (FibroFix cartilage repair experience) study. The company has received a Letter of No Objection from the UK’s MHRA, enabling the start of the study. The study, which is also supported by funding […]

July 13, 2022 - 4 minutesmins - By Jim Cornall

Patient dosed in phase 1 trial evaluating ATG-018 treatment

News and Trends 13 Jul 2022

Development of cancer therapeutics accelerated by end-to-end single-cell multi-omics services

Solid tumor assays have been launched by Mission Bio Inc., through its Pharma Assay Development (PAD) services. The availability of this new service offering from Mission Bio, a high-throughput single-cell DNA and multi-omics analysis company, will help accelerate the development of cancer therapeutics. It will do so by reducing the time and cost associated with […]

July 13, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Jul 2022

Sanofi sells two portfolios of established products to Neuraxpharma

Two drugs portfolios with products to treat the central nervous system, pain and vascular disease have been bought by pharmaceutical company, Neuraxpharm Group. The company bought the portfolios from French healthcare company, Sanofi. Jörg-Thomas Dierks, CEO of Neuraxpharm, said: “There is significant growth potential in the pharmaceutical sector, especially in the CNS market driven […]

July 13, 2022 - 2 minutesmins - By Liza Laws

News and Trends 13 Jul 2022

Report says tech talent is hard to find

Randstad Sourceright’s 2022 life sciences and pharma Talent Trends report finds a third of C-suite and human capital leaders in the life sciences and pharmaceuticals sector say talent scarcity is a major pain point for the sector, which is hiring extensively this year. With demand for life sciences products expected to grow faster than the […]

July 13, 2022 - 4 minutesmins - By Jim Cornall

In Depth 13 Jul 2022

The biggest European biotech investments in June 2022

Oncology and AI-guided drug discovery firms roped in the biggest biotech investments in Europe in June 2022. The leading private rounds went to companies including ImCheck Therapeutics, MiroBio and Charm Therapeutics. In June 2022, we saw bigger private biotech investments in Europe than in May. ImCheck Therapeutics took the top spot; the firm raised an […]

July 13, 2022 - 3 minutesmins - By Jonathan Smith

antibody drug conjugate adc small cancer treatment

News and Trends 12 Jul 2022

Legochem Bioscience signs agreement with Glycotope to develop cancer drug

A company from South Korea has signed a research collaboration and license agreement with a German business to develop a cancer fighting drug. Seoul-based Legochem Biosciences Inc and Berlin-based Glycotope GmbH will develop an antibody drug conjugate (ADC) by combining LBC’s technology with one of Glycotope’s investigational tumor targeting antibodies. ADCs are a class of […]

July 12, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Agomab bags $114 million in thriving regenerative medicine sector

FDA authorizes the first protein-based COVID-19 vaccine in the US

Telo Genomics launches clinical study of drug resistance test for multiple myeloma

Radiopharmaceuticals gain traction for cancer theranostics potential

Paradigm of treatment of mental health to be transformed by gut-brain development program

First aseptic filling line and facilities completed in Taiwan

Orthox green light for knee cartilage repair clinical trial

Development of cancer therapeutics accelerated by end-to-end single-cell multi-omics services

Sanofi sells two portfolios of established products to Neuraxpharma

Report says tech talent is hard to find

The biggest European biotech investments in June 2022

Legochem Bioscience signs agreement with Glycotope to develop cancer drug

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!